Guardant Health Gains as Analyst Target Increase and Strong Growth Expectations Lift Sentiment

Guardant Health (GH) is up 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a fresh analyst price-target increase ahead of next week’s quarterly report, combined with continued optimism around Guardant Health’s fast-growing Shield blood test and broader liquid biopsy business. The move also looks supported by the company’s already strong second-quarter results and higher full-year revenue outlook, which have kept investors focused on another potentially solid update.

Details:

An analyst at BTIG lifted its price target on Guardant Health to $210 from $195 on October 27 while keeping a Buy rating, signaling confidence in near-term momentum.

That analyst note pointed to expectations for a strong third quarter, including Shield test volume well above last year and the possibility of another guidance increase.

In its second-quarter 2026 release, Guardant Health posted 44% revenue growth to $335.0 million and raised full-year revenue guidance to $1.34 billion to $1.36 billion.

Guardant Health is scheduled to report third-quarter 2026 results on November 5, which may be drawing additional positioning from investors expecting another upbeat update.

Sources:

Guardant Health Investor Relations, Investing.com, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GH Insider Trading Activity

$GH insiders have traded $GH stock on the open market 79 times in the past 6 months. Of those trades, 1 have been purchases and 78 have been sales.

Here’s a breakdown of recent trading of $GH stock by insiders over the last 6 months:

AMIRALI TALASAZ (Co-Chief Executive Officer) has made 0 purchases and 22 sales selling 557,500 shares for an estimated $73,748,728.
CHRIS FREEMAN (Chief Commercial Officer) has made 0 purchases and 5 sales selling 88,011 shares for an estimated $13,682,471.
HELMY ELTOUKHY (Co-Chief Executive Officer) has made 0 purchases and 7 sales selling 100,000 shares for an estimated $12,629,968.
TERILYN J. MONROE (Chief People Officer) has made 0 purchases and 5 sales selling 46,300 shares for an estimated $7,645,218.
JOHN G. SAIA (Chief Legal Officer) has made 0 purchases and 5 sales selling 30,000 shares for an estimated $3,381,064.
IAN T CLARK has made 0 purchases and 3 sales selling 21,056 shares for an estimated $2,988,499.
STEVE E. KROGNES has made 0 purchases and 5 sales selling 15,968 shares for an estimated $2,404,407.
KUMUD KALIA (Chief Information Officer) has made 1 purchase buying 600 shares for an estimated $78,456 and 5 sales selling 13,618 shares for an estimated $1,886,542.
DARYA CHUDOVA (Chief Technology Officer) sold 7,738 shares for an estimated $1,377,364
MEGHAN V. JOYCE has made 0 purchases and 4 sales selling 10,000 shares for an estimated $1,269,808.
MEDINA MANUEL HIDALGO has made 0 purchases and 5 sales selling 3,950 shares for an estimated $543,125.
MUSA TARIQ has made 0 purchases and 7 sales selling 2,647 shares for an estimated $358,758.
MICHAEL BRIAN BELL (Chief Financial Officer) sold 2,000 shares for an estimated $257,240
MYRTLE S POTTER sold 1,556 shares for an estimated $204,084
ALEX M II AZAR has made 0 purchases and 2 sales selling 895 shares for an estimated $155,582.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$GH Hedge Fund Activity

We have seen 383 institutional investors add shares of $GH stock to their portfolio, and 213 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. removed 3,930,824 shares (-34.0%) from their portfolio in Q2 2026, for an estimated $589,741,524
BAILLIE GIFFORD & CO removed 2,605,899 shares (-53.3%) from their portfolio in Q2 2026, for an estimated $390,963,026
PIER 88 INVESTMENT PARTNERS LLC removed 2,050,800 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $307,681,524
JANE STREET GROUP, LLC added 1,778,641 shares (+37031.9%) to their portfolio in Q2 2026, for an estimated $266,849,509
AMERIPRISE FINANCIAL INC added 1,736,011 shares (+122.7%) to their portfolio in Q2 2026, for an estimated $260,453,730
FMR LLC added 1,372,191 shares (+33.3%) to their portfolio in Q2 2026, for an estimated $205,869,815
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC added 1,311,320 shares (+inf%) to their portfolio in Q2 2026, for an estimated $196,737,339

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GH Congressional Stock Trading

Members of Congress have traded $GH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GH stock by members of Congress over the last 6 months:

REPRESENTATIVE JONATHAN L. JACKSON purchased up to $50,000 on 09/28.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$GH Price Targets

Multiple analysts have issued price targets for $GH recently. We have seen 14 analysts offer price targets for $GH in the last 6 months, with a median target of $175.0.

Here are some recent targets:

Shannon O'Callaghan from Morgan Stanley set a target price of $175.0 on 07/09/2026
Patrick Donnelly from Citigroup set a target price of $215.0 on 07/08/2026
Michael Ryskin from B of A Securities set a target price of $190.0 on 07/06/2026
Vijay Kumar from Evercore ISI Group set a target price of $200.0 on 07/06/2026
Eve Burstein from Bernstein set a target price of $200.0 on 07/02/2026
Mark Massaro from BTIG set a target price of $190.0 on 07/01/2026
Subbu Nambi from Guggenheim set a target price of $160.0 on 06/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.